The Security Gap Hiding Inside Pharma’s A.I. Revolution
As pharmaceutical companies lean more heavily on A.I. to accelerate drug discovery, model biological interactions and optimize clinical trial design, QuantHealth’s Siwar El Assad argues that the compliance frameworks most organizations rely on to signal security maturity were built for a technological era that A.I. has already left behind.
